Scholtz & Company, LLC Crispr Therapeutics Ag Transaction History

Scholtz & Company, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$70.09 - $111.29 $138,778 - $220,354	-1,980 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $88,711 - $126,095	-805 Reduced 28.9%	1,980 $222,000
Q2 2021 Aug 09, 2021	SELL	$100.84 - $161.89 $6,756 - $10,846	-67 Reduced 2.35%	2,785 $451,000
Q1 2021 May 17, 2021	SELL	$110.72 - $210.04 $8,525 - $16,173	-77 Reduced 2.63%	2,852 $348,000
Q4 2020 Feb 12, 2021	BUY	$79.67 - $173.23 $28,999 - $63,055	364 Added 14.19%	2,929 $448,000
Q3 2020 Nov 16, 2020	BUY	$78.5 - $100.64 $201,352 - $258,141	2,565 New	2,565 $215,000

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.61B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Scholtz & Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Scholtz & Company, LLC with notifications on news.